What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Eli Lilly (LLY) recently faced legal challenges as Texas Attorney General Ken Paxton filed a lawsuit against the company, ...

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Mounjaro, one of the UK’s most popular weight-loss jabs, is set to become more expensive for private patients after Eli Lilly ...

Eli Lilly will raise UK list prices for its Mounjaro weight-loss jab by as much as 170% from September after Donald Trump ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Indianapolis-based Eli Lilly and Co. has operated in Ireland since the late 1970s and has more than 3,500 employees there.